TABLE 2.
List of published sacubitril-valsartan studies reporting QALY gains.
| Authors | Year | Manufacturer funded study | Type of publication | Perspective | Time horizon | Discount rate (benefits) | Source for utilities | QALYs gained |
|---|---|---|---|---|---|---|---|---|
| Liu et al | 2020 | Review | ||||||
| Borges et al | 2020 | N | CUA | Societal | 30 years | 5 | PARADIGM-HF trial | 0.44 |
| Park et al | 2019 | Y | CUA | Health care sector | Lifetime | 5 | General South Korean population | 0.59 |
| Chin et al | 2019 | N | CUA | Health care sector | 20 years | 5 | King et al., 2016 | 0.31 |
| Gandjour et al | 2018 | Y | CUA | SHI | Lifetime | 3 | PARADIGM-HF trial | 0.76 |
| Krittayaphong et al | 2018 | N | CUA | Health care sector | Lifetime | 3 | Gaziano et al., 2016 King et al., 2016 | 0.79 |
| Zueger et al | 2018 | ? | CUA | Payor | 5 years | 3 | Griffiths et al., 2014 | 0.102 |
| McMurray et al | 2018 | Y | CUA | Health care sector | Lifetime | 3.5 | PARADIGM-HF trial | 0.52 |
| McMurray et al | 2018 | Y | CUA | Health care sector | Lifetime | 3 | PARADIGM-HF trial | 0.47 |
| McMurray et al | 2018 | Y | CUA | Health care sector | Lifetime | 5 | PARADIGM-HF trial | 0.42 |
| Liang et al | 2018 | N | CUA | Health care sector | 10 years | 3 | CARE HF | 0.21 |
| Ademi et al | 2017 | Y | CUA | Health care sector | Lifetime | 3 | PARADIGM-HF trial | 0.4254 |
| Ramos et al | 2017 | Y | CUA | Societal | Lifetime | 1.5 | PARADIGM-HF trial | 0.33 |
| van der Pol et al | 2017 | N | CUA | Health care sector | 30 years | 1.5 | SHIFT Study (ivabradine) | 0.29 |
| Sandhu et al | 2016 | N | CUA | Societal | Lifetime | 3 | PARADIGM-HF trial | 0.62 |
| Gaziano et al | 2016 | Y | CUA | Payor | 30 years | 3 | PARADIGM-HF trial | 0.78 |
| King et al | 2016 | N | CUA | Payor | Lifetime | 3 | CARE HF | 0.76 |
| Mean among subset studies (in bold, used for the analysis) | >20 years | 0.5361 |